^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(11;14) + BCL2 overexpression

    i
    Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. (PubMed, Front Oncol)
    Venetoclax, an oral BCL2 inhibitor, has shown remarkable activity in treating relapsed/refractory MM patients with t(11;14) and BCL2 overexpression, either as monotherapy or in combination with other anti-myeloma agents. In this review, we describe the molecular defects associated with the t(11;14), bring into question the standard cytogenetic risk of myeloma patients harboring t(11;14), summarize current efficacy and safety data of targeted venetoclax-based therapies, and discuss the future of individualized or precision medicine for this unique myeloma subgroup, which will guide optimal treatment.
    Review • Journal • IO biomarker
    |
    CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CCND3 (Cyclin D3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    Chr t(11;14) • BCL2 overexpression • Chr t(11;14) + BCL2 overexpression
    |
    Venclexta (venetoclax)